Axiom publishes structured analytical reports across all major financial instrument categories. Reports are designed for investors who need evidence-based analysis, not promotional material. Available in tiered access levels — preview below, full access via subscription.
Comprehensive assessment of the Danish macroeconomic environment heading into the second half of 2024. Covering GDP growth trajectory, inflation normalisation, labour market conditions, housing market dynamics, and Danmarks Nationalbank policy alignment with the ECB.
Detailed valuation analysis of the OMXC25 index constituents, including price-to-earnings, price-to-book, and enterprise value multiples versus historical averages and European peer benchmarks. Sector overweight/underweight recommendations based on relative valuation and earnings momentum.
In-depth analysis of Danish mortgage bond (realkreditobligation) market dynamics. Covers yield spread versus German Bunds, prepayment risk modelling, callable versus non-callable bond mechanics, and recommended duration positioning given the ECB rate cycle trajectory.
Structural supply-demand analysis of the metals most critical to the global energy transition. Projects copper deficit scenarios, lithium price normalisation timelines, and nickel market supply disruption risks. Includes equity sector implications for mining and materials allocations.
Analysis of the European Central Bank's policy trajectory, peak rate probability distributions, and the timeline for rate normalisation. Includes implications for duration risk across European sovereign, covered bond, and corporate bond markets — with specific Danish realkreditobligation considerations.
Comprehensive comparison of the leading UCITS-compliant global equity ETFs available to Danish investors. Evaluates TER, tracking difference, replication method, Irish/Luxembourg domicile tax advantages, lagerbeskatning versus minimumsbeskatning classification, and bid-ask spread data from Euronext Copenhagen listings.
Detailed analysis of Nordic life sciences equity valuations in the context of Novo Nordisk's extraordinary GLP-1 drug success and its distorting effect on OMXC25 sector weights. Examines Genmab, Lundbeck, Bavarian Nordic, and Leo Pharma on standalone and comparative bases.
Assessment of European high-yield bond market conditions. Analyses current spread levels versus historical averages, default rate projections by sector, recovery rate assumptions, and identifies potential selective value in BB-rated issuers with improving credit trajectories.
Annual flagship report. Covers global growth scenarios, inflation paths across major economies, the implications of central bank policy normalisation for all asset classes, and Axiom's strategic asset allocation recommendations for Danish investor portfolios in 2024.
Access the full Axiom research library with a subscription. New reports are published weekly.
View Subscription Plans